Skip to main content
OpenTrials
Completed

NCT Number: NCT01030952

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

A 3-week, multi-center, open-label, randomized, active-control, parallel-group study to compare effects of Nateglinide and Acarbose on postprandial glucose fluctuation in Chinese drug-naive patients type 2 diabetes mellitus (T2DM). In this study, participants in different groups took Nateglinide at a dose of 120 mg orally three times daily for up to 3 weeks or Acarbose at a dose of 50 mg three times daily for up to 3 weeks, respectively.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must give written informed consent before any assessment is performed.
  • Male, non-fertile female or female of childbearing potential using a medically approved birth control method based on local regulations.
  • Drug naïve type 2 diabetes patients, defined as who neither take consecutive anti-hyperglycemic drug treatment more than 3 months anytime, nor any anti-hyperglycemic drug treatment in 4 weeks prior to visit 1.
  • Age in the range of 18-75 years inclusive.
  • HbA1c in the range of > 6.5 to ≤9.0% at Visit 1.

Exclusion criteria

  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/mL).
  • With known hypersensitivity to Nateglinide, Acarbose or any of the excipients.
  • A history of,
  • type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.
  • acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months.
  • Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation.
  • percutaneous coronary intervention within the past 3 months.
  • any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery, unstable angina, or stroke.
  • Evidence of significant diabetic complications, e.g., symptomatic autonomic neuropathy or gastroparesis.
  • Acute infections which may affect blood glucose control within 4 weeks prior to visit 1.
  • Congestive heart failure requiring pharmacologic treatment. mg/dL (123μmol/L)

Treatment and study plan

nateglinide

Drug

Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.

Acarbose

Drug

Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.

Primary outcomes

  1. Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS)

    Time frame: 3 weeks (end of study) minus baseline

    The postprandial glucose area under the curve (AUC)was calculated using values from the 3 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.

    0-4 hours AUC were calculated using trapezoid methods.

Secondary outcomes

  1. Change in Incremental Glucose Peak (IGP) From Baseline

    Time frame: baseline, 3 weeks (end of study)

    Incremental glucose peak (IGP) was the maximal incremental increase in blood glucose obtained at any point after meal

  2. Change in Mean Blood Glucose (MBG)

    Time frame: baseline and at 3 weeks (end of study)

    The 24 hour mean blood glucose (MBG) level was calculated as the mean of all the consecutive readings on baseline and end of study(3 weeks later) separately.

  3. Change in Standard Deviation (SD) From Baseline of Mean Blood Glucose (MBG) Over 24 Hours.

    Time frame: baseline, 3 weeks (end of study)

    Change in standard deviation (SD) from baseline of mean blood glucose (MBG) describes the range of blood glucose fluctuation over 24 hours.

  4. Change in Mean of Daily Difference of Paired Blood Glucose Value (MODD)

    Time frame: baseline, 3 weeks (end of study)

    The mean of the daily differences (MODD), calculated as the average absolute difference of paired glucose values during two successive 24 hour periods, was used to assess day-to-day glycaemic variability.

  5. Changes in 24 Hour Glucose Area Under Curve (AUCpp)

    Time frame: baseline, end of study (3 weeks)

    Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.

  6. Change in Glycated Serum Albumin (GSA) Levels From Baseline After Treatment

    Time frame: baseline, 3 weeks (end of study)

    GSA levels were to be determined by CGMS at 7:00~10:00 am in the 4-hour standardized meal test before treatment after overnight fasting for efficacy assessments

  7. Change in Insulin Levels (μU/ml) During Standardized Meal Test at Endpoint From Baseline

    Time frame: baseline, 3 weeks (end of study)

    This outcome measure calculated the change in insulin levels between groups over time at 0, 30 then 120 minutes

  8. Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Time frame: baseline, 3 weeks (end of study)

    change in LDL-C at 0, 30 and 120 minutes

  9. Change of Total Cholesterol in Blood Lipids Levels During Standardized Meal Test at Endpoint From Baseline at Each Time Point

    Time frame: baseline, 3 weeks (end of study)

    time to change in Total Cholesterol blood lipids level at 0, 30, 120 minutes

  10. Change in Triglyceride (TG)Levels in Blood Lipid Levels During Standardized Meal Test at Endpoint

    Time frame: baseline, 3 weeks (end of study)

    TG change in blood lipids level from baseline to endpoint

  11. Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study

    Time frame: baseline, 3 weeks (end of study)

    Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 3. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value.

  12. Change in Mean Amplitude of Glycaemic Excursion (MAGE)

    Time frame: baseline, 3 weeks (end of study)

    mean amplitude of glycaemic excursion (MAGE) is an average of the amplitudes of all glycemic excursions greater than a prespecified threshold size

  13. The Percent of 24 Hour Hypoglycemic Measurements

    Time frame: baseline, 3 weeks (end of study)

    Measures/compares changes in percentage of hypoglycemia(<3.9mmol/l or <70 mg/dl) in glucose measurements in 24hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values [100% * ((X-Y)/Y)]

  14. Change in Percent of 24 Hour Hyperglycemic Measurements

    Time frame: baseline, 3 weeks (end of study)

    Measures/compares changes in percentage of hyperglycemia (>7.8mmol/l or 140 mg/dl) in glucose measurements in 24 hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values [100% * ((X-Y)/Y)]

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Dec 14, 2009
Registry last updated
Oct 19, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.